Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$1.93
-$0.09(-4.55%)
At close: 4:00 PM EST
$1.93
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)871.78K
Market Cap
$210.66M
Enterprise Value$172.03M
Total Cash (Recent Filing)$291.11M
Total Debt (Recent Filing)$37.88M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 03, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding109,151,474
10 Day Avg. Volume736,388
30 Day Avg. Volume871,780
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.44
Price to Sales (P/S)1.82
P/FCF Ratio-0.79
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit7.62
Enterprise Value/Ebitda-1.53
Forecast
1Y Price Target
$2.10Price Target Upside8.81% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial RunwayRestructuring extended the company's cash runway through 2027 and is positioned to fund two ABC assets into the clinic, reducing near-term financing pressure.
Pipeline MilestonesPlanned IND submissions for AL137 and AL050 would advance first-in-class ABC-derived programs into clinical development, potentially validating the platform's translational potential.
Platform StrategyAlector's Alector Brain Carrier (ABC) platform enables delivery of antibodies, enzymes, and siRNA across the blood-brain barrier, creating differentiated therapeutic opportunities in large central nervous system markets.
Bears Say
Analyst Sentiment And ValuationAnalyst downgrades and lowered price targets following the discontinuation of latozinemab may increase downward pressure on the stock by reducing investor confidence.
Clinical Failure ImplicationsThe Phase III failure of latozinemab to demonstrate clinical benefit undermines confidence in progranulin-targeting and raises questions about SORT1 as a viable therapeutic target.
Operational RiskA substantial workforce reduction and pipeline narrowing indicate operational strain that could delay programs and impair execution.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $3.40 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $210.66M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Mar 03, 2026 which is in 26 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Nov 06, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.408 by $0.068.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.38.
How many shares outstanding does Alector Inc have?
Alector Inc has 109,151,474 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.408. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.10 (8.81% Upside)
$2.10 (8.81% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 158.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $212.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 13.4%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.68%
12-Months-Change
Fundamentals
Return on Equity
-121.98%
Trailing 12-Months
Asset Growth
-35.03%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$2.10
▲(8.81% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---